p16INK4A and p15INK4B gene deletions in primary leukemias.

Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med (2007) 1.47

Biallelic mutations in p16(INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts. Mol Cell Biol (2002) 1.36

Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. Mol Cell Biol (2001) 0.98

Analyzing the gene expression profile of pediatric acute myeloid leukemia with real-time PCR arrays. Cancer Cell Int (2012) 0.90

Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. Leukemia (2014) 0.85

Loss of function tp53 mutations do not accelerate the onset of myc-induced T-cell acute lymphoblastic leukaemia in the zebrafish. Br J Haematol (2014) 0.77

Genome organization and the role of centromeres in evolution of the erythroleukaemia cell line HEL. Evol Med Public Health (2013) 0.77

p15(INK4b) plays a crucial role in murine lymphoid development and tumorigenesis. Carcinogenesis (2012) 0.75

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35

The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50

Superoxide dismutase as a target for the selective killing of cancer cells. Nature (2000) 3.44

Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 3.19

Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood (1997) 3.14

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia (2012) 2.80

Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood (1999) 2.79

Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology (1993) 2.79

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 2.78

Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia (2003) 2.60

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med (2001) 2.60

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood (2000) 2.53

Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res (2001) 2.41

Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol (1999) 2.38

The prevalence and effects of hunger in an emergency department patient population. Acad Emerg Med (1999) 2.24

The human MDM-2 oncogene is overexpressed in leukemias. Blood (1993) 2.24

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood (2001) 2.14

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol (1988) 2.06

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood (1999) 1.99

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol (2001) 1.96

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer (1999) 1.90

Chronic myelogenous leukemia: biology and therapy. Ann Intern Med (1999) 1.87

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med (1986) 1.86

Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica (2000) 1.81

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia (2008) 1.79

Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood (1999) 1.76

Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia (2003) 1.76

Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. Bioinformatics (2004) 1.72

DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res (2001) 1.71

Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol (1997) 1.69

Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol (2001) 1.65

HIV infection and AIDS in China, 1985 through 1994. Am J Public Health (1996) 1.64

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia (2009) 1.63

Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia (2002) 1.62

Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer (1988) 1.62

Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood (1999) 1.57

Is hypertension associated with hemifacial spasm? Neurology (2003) 1.56

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia (2010) 1.54

Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol (1986) 1.54

MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia (2008) 1.53

2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood (1992) 1.52

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol (1999) 1.51

Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res (2001) 1.51

Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant (2004) 1.50

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res (1990) 1.50

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia (2012) 1.49

High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant (2007) 1.48

Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood (1992) 1.48

Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma (1993) 1.45

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia (2012) 1.44

Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia (2001) 1.44

Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood (2001) 1.43

Evolving spectrum of movement disorders in extrapontine and central pontine myelinolysis. Parkinsonism Relat Disord (2002) 1.42

Factors related to length of complete remission in adult acute leukemia. Cancer (1980) 1.42

Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. Am J Med (1992) 1.41

A young man with parkinsonism. J R Soc Med (2002) 1.40

Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia. Br J Haematol (2006) 1.40

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood (2001) 1.39

A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood (1985) 1.39

Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol (2001) 1.39

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia (2009) 1.38

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol (1993) 1.38

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia (2012) 1.37

Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia (1996) 1.36

A randomized comparative trial of three aminoglycosides--comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine (Baltimore) (1979) 1.36

Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol (2005) 1.32

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med (1987) 1.30

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer (2001) 1.28

ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res (1999) 1.26

Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood (1998) 1.26

Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology (2007) 1.25

The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood (1995) 1.24

Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. Arch Intern Med (1984) 1.24

Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc (2000) 1.23

Malignant gingival and skin "infiltrates" in adult leukemia. Oral Surg Oral Med Oral Pathol (1983) 1.23

Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia (1989) 1.22

Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood (1998) 1.22

Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia (2008) 1.21

A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med (1992) 1.21

Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood (1997) 1.20

Monophasic, solitary tumefactive demyelinating lesion: neuroimaging features and neuropathological diagnosis. Br J Radiol (2004) 1.20

Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia (2004) 1.20

Richter's syndrome: a report on 39 patients. J Clin Oncol (1993) 1.19